Prof Niall Tebbutt
Clinical (Professor)
Department of Surgery
459 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
DOI: 10.1200/jco.2026.44.16_suppl.41012026
Journal article
Zanidatamab chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2 ) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.
DOI: 10.1200/jco.2026.44.16_suppl.40102026
Journal article
Real-world treatment patterns and clinical outcomes for patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.16_suppl.e155502026
Journal article
A phase 1/2 study of BDC-4182, a Claudin 18.2–targeting next-generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer.
DOI: 10.1200/jco.2026.44.16_suppl.tps42422026
Journal article
Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2 ) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
DOI: 10.1200/jco.2026.44.16_suppl.40422026
Journal article
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
DOI: 10.1056/NEJMoa25177292017
Research Grant
Mapping Patterns of Care for People With Pancreatic Cancer: How Close Are We to the Optimal Care Pathway Recommendations?
RECENT SCHOLARLY WORKS
2026
Journal article
Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature
DOI: 10.1016/j.xcrm.2026.1026942026
Journal article
Abstract CT094: A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer
DOI: 10.1158/1538-7445.am2026-ct0942026
Journal article
Abstract CT183: Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer
DOI: 10.1158/1538-7445.am2026-ct1832026
Journal article
From chemotherapy to molecular targeted therapy in advanced biliary tract cancer
DOI: 10.20935/acadonco8171